<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00963001</url>
  </required_header>
  <id_info>
    <org_study_id>TDE-PH-115</org_study_id>
    <nct_id>NCT00963001</nct_id>
  </id_info>
  <brief_title>Effect of Food on the Pharmacokinetics of Oral Treprostinil</brief_title>
  <official_title>Effect of Different Meal Types on the Pharmacokinetics of a Single 1 mg Oral Dose of UT-15C (Treprostinil Diethanolamine) Sustained Release Tablets in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>United Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacokinetic and safety profile of a single
      dose of oral treprostinil following four different meals of varying caloric and fat content.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treprostinil pharmacokinetics in healthy volunteers following a single oral dose of a 1 mg treprostinil diethanolamine sustained release tablet after four different meal types.</measure>
    <time_frame>Immediately prior to through 36 hours post treprostinil diethanolamine dosing for each treatment period (4 treatment periods each separated by a 7-day washout period)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse event monitoring</measure>
    <time_frame>From the first dose of treprostinil diethanolamine through study end (Study Day 23/24)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratories</measure>
    <time_frame>Study Days 0, 7, 14, 21 and 23</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <condition>Pulmonary Arterial Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treprostinil diethanolamine</intervention_name>
    <description>Subjects will each receive a single 1 mg sustained release tablet of treprostinil diethanolamine by mouth within 10 minutes of consuming each of four standardized meals on Study Days 1, 8, 15, and 22.</description>
    <other_name>UT-15C</other_name>
    <other_name>UT-15C SR</other_name>
    <other_name>Oral treprostinil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standardized meals</intervention_name>
    <description>Each subject will receive one of four different standardized meals of varying caloric and fat content in a randomized sequence such that all subjects will receive all four meals over the course of the study. Each subject will receive one standardized meal for breakfast on Study Days 1, 8, 15, and 22.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is healthy and between the ages of 18 and 55 years, inclusive, at Screening.

          -  Female subjects must weigh between 45 and 100 kg, inclusive, with a BMI between
             19.0-29.9 kg/m2, inclusive at Screening. Male subjects must weigh between 50 and 120
             kg, inclusive, with a BMI between 19.0-32.0 kg/m2, inclusive at Screening.

          -  Subject has a medical history, physical examination, vital signs, ECG and clinical
             laboratory results within normal limits or considered not clinically significant by
             the Investigator at Screening.

        Exclusion Criteria:

          -  Subject has any clinically relevant abnormality identified during the screening
             physical examination, 12-lead ECG, or laboratory examinations.

          -  Subject has a history of anaphylaxis, a documented hypersensitivity reaction, or a
             clinically significant idiosyncratic reaction to any drug.

          -  Subject has a clinically significant history of neurological, cardiovascular,
             respiratory, endocrine, hematological, hepatic, renal, gastrointestinal,
             genitourinary, pulmonary, and/or musculoskeletal disease; glaucoma; a psychiatric
             disorder, or any other chronic disease, whether controlled by medication or not.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aziz Laurent, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PPD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Development</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2009</study_first_submitted>
  <study_first_submitted_qc>August 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2009</study_first_posted>
  <last_update_submitted>March 5, 2010</last_update_submitted>
  <last_update_submitted_qc>March 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Allison Pecha</name_title>
    <organization>United Therapeutics Corp.</organization>
  </responsible_party>
  <keyword>Hypertension, Pulmonary</keyword>
  <keyword>Treprostinil</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Treprostinil Diethanolamine</keyword>
  <keyword>Pulmonary Arterial Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Treprostinil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

